Latest Headlines

Latest Headlines

Should gastro specialist Salix snap up Furiex and its IBS drug candidate?

Should Salix Pharmaceuticals snap up its North Carolina neighbor Furiex Pharmaceuticals? The latter's bowel drug could slide right in to Salix's business, analysts said. And Furiex is scouting around for a potential buyer, Bloomberg reports.

With a $300M buyout fund, Maravai sets out to make a biotech splash

Private equity outfit GTCR has recruited two industry veterans and put up $300 million to create Maravai Life Sciences, a buyout-focused firm out to make some deals.

Proteon sets out on its own after Novartis waves off a $550M deal

Five years after optioning the right to buy Proteon Therapeutics for up to $550 million, Novartis has walked away from the table despite what Proteon says was a successful study of its blood vessel-dilating drug, leaving the biotech to fend for itself as it prepares for Phase III.

Report: Novartis circles a deal to buy Gamida Cell in $600M deal

Israel's Globes is reporting that Novartis is pursuing a deal to buy out Israel's Gamida Cell for "hundreds of millions" of dollars upfront and hundreds of millions more in milestones, adding up to a total of about $600 million.

Meet DPx, the result of a $2.6B CMO merger

A $2.6 billion deal united contract manufacturers Patheon and DSM Pharmaceutical Products, and now the combined company has emerged to do business under the monicker DPx, expecting to bank $2 billion in revenue this year.

Post-merger BioClinica looks to corner the imaging market

BioClinica has come out the other side of its second merger in as many years, absorbing CCBR-Synarc and plotting to shift its focus toward medical imaging and specialty services for clinical trials.

Thermo Fisher beefs up its animal health Dx offerings with a Swiss acquisition

A little over a month after Thermo Fisher closed its gigantic $13.6 billion buyout of Life Technologies, it has completed the acquisition of Prionics AG, a privately held Swiss animal health diagnostics company.

Chelsea Therapeutics and the return of pharma's phantom checkbook

Chelsea Therapeutics saw its shares soar roughly 15% on Thursday thanks to rumors that it could be in line for a Big Pharma buyout. But a deeper look at the issue reveals neither market-wide chatter nor unnamed-source speculation; just a single analyst reading of tea leaves, leading to what could be yet another disparity between smoke and fire in the biopharma M&A world.

Sorin snatches up a Florida manufacturer's cardiac-lead business for $20M

Sorin Group is paying $20 million for a Florida manufacturer's cardiac-lead business, as well as its plans for new MRI-compatible cardiac leads.

Galapagos ships out its CRO biz for $179M to focus on R&D

Belgian biotech Galapagos is getting out of the CRO business, selling off its two contract units to preclinical giant Charles River Laboratories for $179 million and planning to put the proceeds into its pipeline.